In the NHANES III cohort of 7,072 individuals, a clinically raised (≥1.00 mg/dl) baseline serum CRP was associated with approximately 2.5-times greater risk of CRC death (Swede et al. 2014). This evidence concerns the gene CRP and colorectal carcinoma.